January 29, 2024 -- the Food and Drug Administration approved erdafitinib (Balversa, Janssen Biotech) for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alter……
January 8, 2024-Novo Nordisk today announced topline results from the COMBINE 3 phase 3a trial of once-weekly IcoSema, a fixed-ratio combination of basal insulin icodec and semaglutide. COMBINE 3 was a 52-week, open……
December 20, 2023 -- Calliditas Therapeutics AB, today announced that the U.S. Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults……
December 25, 2023 -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), today announced the U.S. Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for t……
Recently, according to Fierce Pharma, unable to scale up its manufacturing fast enough to meet the spiraling demand for its GLP-2 weight loss products, Novo Nordisk is employing a new strategy—reducing production of diab……
The US Food and Drug Administration (FDA) announced on November 8, 2023 that Lilly's Zepbound injection was approved for long-term weight management of adults, which is applicable to obese or overweight adults (BMI i……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
